Magenta Therapeutics (Magenta Therapeutics) 3-Year Revenue Growth Rate : 0.00% (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Magenta Therapeutics 3-Year Revenue Growth Rate?

Magenta Therapeutics's Revenue per Share for the three months ended in Jun. 2023 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Competitive Comparison of Magenta Therapeutics's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Magenta Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Magenta Therapeutics's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Magenta Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Magenta Therapeutics's 3-Year Revenue Growth Rate falls into.

Magenta Therapeutics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Magenta Therapeutics (NAS:MGTA) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Magenta Therapeutics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Magenta Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Magenta Therapeutics (Magenta Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Magenta Therapeutics Inc (NAS:MGTA) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Technology Square, 5th Floor, Cambridge, MA, USA, 02139

Website

https://www.magentatx.com

Magenta Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy. The pipeline of the company includes MGTA-117, MGTA-145, MGTA-45 and others.

Executives

Peter Evan Harwin	director, 10 percent owner	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Tomas Kiselak	director, 10 percent owner	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Funds Management Llc	director, 10 percent owner	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Edward Carr	officer: CHIEF ACCOUNTING OFFICER	1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Ryan Savitz	officer: CHIEF FINANCIAL OFFICER	7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Lei Meng	director	7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Simrat Randhawa	officer: Chief Medical Officer	7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Avidity Partners Management Lp	director	2828 N HARWOOD STREET, SUITE 1220, DALLAS TX 75201
Marino Garcia	director, officer: CEO and President	C/O SYNERGY PHARMACEUTICALS INC., 420 LEXINGTON AVENUE, SUITE 2012, NEW YORK NY 10170
Adam M Veness	officer: See Remarks	C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Moulder Leon O Jr	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Paula Soteropoulos	director	49 WINONA STREET, PEABODY MA 01960
Jonathan Violin	director	955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Third Rock Ventures Iv, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Michael Vasconcelles	director	C/O UNUM THERAPEUTICS, 200 CAMBRIDGEPARK DR., STE. 3100, CAMBRIDGE MA 02140